Skip to main content
. Author manuscript; available in PMC: 2023 Feb 9.
Published in final edited form as: Gynecol Oncol. 2022 Jul 5;166(3):425–431. doi: 10.1016/j.ygyno.2022.06.017

Fig. 1.

Fig. 1.

Patient assignment to cohorts in the LIGHT study.

The Myriad myChoice® HRD assay was FDA-approved as a companion diagnostic assay for olaparib in October 2019 and renamed myChoice CDx®. BRCAm, BRCA1 and/or BRCA2 mutation; FDA, US Food and Drug Administration; gBRCAm, germline BRCAm; GIS, genomic instability score; HRD, homologous recombination deficiency; LIGHT, oLaparib In Germline-, HRD-, and Tumor-mutated versus wild-type ovarian cancer; sBRCAm, somatic BRCA mutation.